Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALUE trial of EscharEx for debridement of venous leg ulcers
2024-519623-23-00Phase 3Authorised
- Sponsor
- MediWound
- Start
- Oct 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in stasis ulcer comparing EscharEx with Placebo (2 arms). Primary endpoints: Incidence of complete debridement and Time to complete wound closure. Planned start Oct 2025; status: authorised.
02
Drugs
EscharEx
03
Conditions
stasis ulcer
Beyond the preview
Go deeper on 2024-519623-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519623-23-00.